CCDC12 Inhibitors
CCDC12 inhibitors encompass a diverse array of chemical compounds that indirectly attenuate the functional activity of CCDC12 through modulation of various cellular signaling pathways. For instance, Staurosporine and Chelerythrine diminish CCDC12's activity by inhibiting protein kinases and PKC, respectively, which are crucial for the phosphorylation processes that CCDC12 relies on. Similarly, tyrosine kinase inhibitors like Genistein could impede the activation of CCDC12 by obstructing the phosphorylation it necessitates. Furthermore, PI3K inhibitors, namely LY 294002 and Wortmannin, along with the mTOR inhibitor Rapamycin, impair the PI3K/AKT/mTOR signaling axis, consequently leading to the down-regulation of CCDC12-dependent processes. Such inhibition denotes how crucial the PI3K/AKT/mTOR pathway is for the functional prowess of CCDC12, as any disturbance in this pathway results in a significant decrement in CCDC12 activity.
The MAPK pathway inhibitors, including PD 98059, SB 203580, SP600125, and U0126, demonstrate the interconnectedness of CCDC12 with the MAPK signaling network by significantly reducing its activity through the inhibition of MEK, p38, and JNK. Each of these compounds specifically targets a component of the MAPK pathway, thereby preventing the necessary signaling required for CCDC12's role in cellular functions. The G-protein signaling inhibitor NF449 further exemplifies the breadth of pathways influencing CCDC12, as it hinders CCDC12's activity by obstructing Gs-alpha subunit-mediated signaling. In a similar vein, Gö 6983's broad-spectrum inhibitory effect on PKC isoforms elucidates the dependency of CCDC12 on PKC-mediated phosphorylation events, underscoring the complexity of CCDC12 regulation. Collectively, CCDC12 inhibitors act by targeting specific biochemical routes, ultimately leading to the suppression of CCDC12's functional engagement in cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which are integral in various signaling pathways. By inhibiting protein kinases that phosphorylate specific substrates required for CCDC12 activity, staurosporine indirectly leads to the diminished functional activity of CCDC12 by preventing its essential post-translational modifications. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, can hinder the phosphorylation of proteins involved in the signaling pathways that CCDC12 is part of. This inhibition can prevent the activation of CCDC12 that relies on tyrosine phosphorylation, thus reducing its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a specific inhibitor of PI3K, a kinase involved in the PI3K/AKT pathway. By inhibiting PI3K, LY 294002 indirectly diminishes the AKT-mediated cellular processes that are necessary for CCDC12 activity, thereby resulting in the reduced functional activity of CCDC12. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin acts as an inhibitor of PI3K. By inhibiting PI3K, it diminishes the activation of downstream AKT signaling, which may be crucial for CCDC12 function. The reduced PI3K/AKT signaling hence indirectly leads to a decrease in CCDC12 functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and forms a complex that inhibits mTOR, a central component of the PI3K/AKT/mTOR pathway. The inhibition of mTOR signaling can indirectly lead to a decrease in CCDC12 activity by altering the cell's response to growth signals that rely on the functional activity of CCDC12. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which functions upstream of ERK in the MAPK pathway. The inhibition of MEK leads to decreased ERK activation, which may be necessary for CCDC12's biological processes. Consequently, the functional activity of CCDC12 is diminished due to the lack of ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is an inhibitor of p38 MAPK. By targeting p38 MAPK, it blocks the signaling that may be essential for CCDC12's role. The inhibition of p38 MAPK signaling thus leads to a decrease in CCDC12 functional activity as the pathway's influence on CCDC12 is reduced. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK pathway. Inhibition of JNK signaling can indirectly lead to decreased CCDC12 activity if CCDC12 relies on JNK-mediated signaling for its function. The result is a diminishment in CCDC12's role within the cell due to impaired JNK pathway activation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of ERK. If CCDC12 activity is contingent on ERK signaling, the use of U0126 would lead to diminished CCDC12 activity by blocking the necessary ERK-mediated processes that contribute to CCDC12's functional role. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Chelerythrine is a selective inhibitor of protein kinase C (PKC). By inhibiting PKC, it can indirectly decrease the activity of CCDC12 if PKC is involved in the signaling pathways or post-translational modifications necessary for CCDC12's function. Thus, CCDC12 activity is reduced due to inhibited PKC signaling. | ||||||